
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Eylea 8 mg (aflibercept 8 mg) for treating neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Based on positive PULSAR and PHOTON clinical trial results, the higher-dose aflibercept demonstrated remarkable durability, requiring fewer injections. Michael Devoy, CMO at Bayer Pharmaceuticals, highlights Eylea 8 mg's transformative potential in retinal care, providing extended treatment intervals and reducing the disease burden. The approval follows similar authorizations in the U.S. and the European Union, marking a significant advancement in retinal disease management.
Like
Save
Share